BR9808720A - Carprofeno seletivo para cox-2 para tratamento de dor e inflamação em cães - Google Patents
Carprofeno seletivo para cox-2 para tratamento de dor e inflamação em cãesInfo
- Publication number
- BR9808720A BR9808720A BR9808720-7A BR9808720A BR9808720A BR 9808720 A BR9808720 A BR 9808720A BR 9808720 A BR9808720 A BR 9808720A BR 9808720 A BR9808720 A BR 9808720A
- Authority
- BR
- Brazil
- Prior art keywords
- cox
- activity
- dogs
- acids
- carprofen
- Prior art date
Links
- 241000282472 Canis lupus familiaris Species 0.000 title abstract 3
- 230000004054 inflammatory process Effects 0.000 title abstract 3
- 206010061218 Inflammation Diseases 0.000 title abstract 2
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 title abstract 2
- 229960003184 carprofen Drugs 0.000 title abstract 2
- 101150071146 COX2 gene Proteins 0.000 title 1
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 title 1
- 101150000187 PTGS2 gene Proteins 0.000 title 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 abstract 5
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 abstract 5
- 230000000694 effects Effects 0.000 abstract 5
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 3
- 230000005764 inhibitory process Effects 0.000 abstract 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 abstract 2
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 abstract 2
- 150000007513 acids Chemical class 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical class NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 abstract 1
- 101100496968 Caenorhabditis elegans ctc-1 gene Proteins 0.000 abstract 1
- 108010037464 Cyclooxygenase 1 Proteins 0.000 abstract 1
- 101100221647 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cox-1 gene Proteins 0.000 abstract 1
- 101150062589 PTGS1 gene Proteins 0.000 abstract 1
- 235000011054 acetic acid Nutrition 0.000 abstract 1
- PDODBKYPSUYQGT-UHFFFAOYSA-N acetic acid;1h-indene Chemical compound CC(O)=O.C1=CC=C2CC=CC2=C1 PDODBKYPSUYQGT-UHFFFAOYSA-N 0.000 abstract 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- -1 heteroaryl acetic acids Chemical class 0.000 abstract 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Patente de Invenção: <B>"CARPROFENO SELETIVO PARA COX-2 PARA TRATAMENTO DE DOR E INFLAMAçãO EM CãES"<D>. Tratamento ou prevenção de processos e doenças inflamatórios em cães associados com a atividade da ciclo-oxigenase-2 (COX-2) indutível, reduzindo ou eliminando ao mesmo tempo efeitos colaterais indesejáveis associados com a inibição simultânea da atividade da ciclooxigenase-1 (COX-1) constitutiva inibindo seletivamente a atividade de COX-2 em relação à atividade de COX-1, em que a razão de seletividade ou inibição da atividade de COX-2: COX-1 é de pelo menos 3 : 1 com base em níveis de inibição ex vivo medidos em sangue completo; o inibidor é um membro selecionado a partir do grupo de compostos antiinflamatórios que consiste essencialmente em derivados do ácido salicílico, derivados de p-aminofenol, ácido indol e indeno acéticos; ácidos heteroaril acéticos, ácidos arilpropiónicos, ácido antranílicos, ácidos enólicos e alcanonas; o inibidor em particular é constituído pelo enantiómero (+) (S) do ácido 6-cloro-<244>-metil-9H-carbazol-2-acético.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4563597P | 1997-05-05 | 1997-05-05 | |
| PCT/IB1998/000662 WO1998050033A1 (en) | 1997-05-05 | 1998-05-01 | Cox-2 selective carprofen for treating pain and inflammation in dogs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9808720A true BR9808720A (pt) | 2000-07-11 |
Family
ID=21939053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9808720-7A BR9808720A (pt) | 1997-05-05 | 1998-05-01 | Carprofeno seletivo para cox-2 para tratamento de dor e inflamação em cães |
Country Status (32)
| Country | Link |
|---|---|
| EP (1) | EP0988034A1 (pt) |
| JP (1) | JP2000513020A (pt) |
| KR (2) | KR20040004406A (pt) |
| CN (1) | CN1255059A (pt) |
| AP (1) | AP9801234A0 (pt) |
| AR (2) | AR011726A1 (pt) |
| AU (1) | AU6932198A (pt) |
| BG (1) | BG103852A (pt) |
| BR (1) | BR9808720A (pt) |
| CA (1) | CA2288759A1 (pt) |
| DZ (1) | DZ2479A1 (pt) |
| EA (1) | EA003696B1 (pt) |
| GT (1) | GT199800063A (pt) |
| HR (1) | HRP980244A2 (pt) |
| HU (1) | HUP0001286A3 (pt) |
| ID (1) | ID21311A (pt) |
| IL (1) | IL132570A0 (pt) |
| IS (1) | IS5220A (pt) |
| MA (1) | MA26491A1 (pt) |
| NO (1) | NO995389L (pt) |
| NZ (1) | NZ500183A (pt) |
| OA (1) | OA11213A (pt) |
| PA (1) | PA8450601A1 (pt) |
| PE (1) | PE72599A1 (pt) |
| PL (1) | PL337003A1 (pt) |
| SK (1) | SK148199A3 (pt) |
| TN (1) | TNSN98059A1 (pt) |
| TW (1) | TW590773B (pt) |
| UY (1) | UY24989A1 (pt) |
| WO (1) | WO1998050033A1 (pt) |
| YU (1) | YU55899A (pt) |
| ZA (1) | ZA983722B (pt) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6245797B1 (en) | 1997-10-22 | 2001-06-12 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease |
| AU2003204888B2 (en) * | 1998-05-22 | 2005-07-28 | Pfizer Products Inc. | Treating or Preventing the Early Stages of Degeneration of Articular Cartilage or Subchondral Bone in Mammals Using Carprofen and Derivatives |
| US6506785B2 (en) | 1998-05-22 | 2003-01-14 | Pfizer, Inc. | Treating or preventing the early stages of degeneration of articular cartilage or subchondral bone in mammals using carprofen and derivatives |
| JP2002528413A (ja) * | 1998-10-23 | 2002-09-03 | メルク フロスト カナダ アンド カンパニー | Ｅ型プロスタグランジンリガンド及びｃｏｘ−２選択的阻害剤を含む配合剤及び使用方法 |
| ATE306263T1 (de) * | 1999-03-10 | 2005-10-15 | Searle Llc | Zusammensetzungen zur verabreichung eines cyclooxygenase-2-hemmers an tiere |
| WO2001034204A1 (en) * | 1999-11-11 | 2001-05-17 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
| CA2407469A1 (en) * | 2000-05-15 | 2001-11-22 | Merck Frosst Canada & Co. | Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor |
| KR20030019422A (ko) | 2000-06-13 | 2003-03-06 | 와이어쓰 | Ｃｏｘ-２저해제를 함유하는 진통성 및 항-염증성 조성물 |
| DE10032132A1 (de) * | 2000-07-01 | 2002-01-17 | Lohmann Therapie Syst Lts | Dermales Therapeutisches System enthaltend nichtsteroidale Antiphlogistika mit selektiver COX-2-Hemmung |
| ATE420201T1 (de) | 2000-08-07 | 2009-01-15 | Univ Vanderbilt | Nachweis der cox-2 aktivität und von anandamid- metaboliten |
| AU2002354901A1 (en) * | 2001-07-16 | 2003-03-03 | Edward Hogestatt | Compounds with analgesic, antipyretic and/or anti-inflammatory activity |
| WO2004098619A2 (en) | 2003-05-07 | 2004-11-18 | Osteologix A/S | Treating cartilage / bone conditions with water-soluble strontium salts |
| WO2005009436A1 (en) * | 2003-07-31 | 2005-02-03 | Pharmacia & Upjohn Company Llc | Dispersible formulation of an anti-inflammatory agent |
| WO2006123247A2 (en) * | 2005-05-20 | 2006-11-23 | Pfizer Limited | Synergistic combinations of non-steroidal antiinflammatory drugs with alpha-delta-ligands |
| EP2061440A2 (en) | 2007-04-04 | 2009-05-27 | Sigmoid Pharma Limited | A pharmaceutical composition of tacrolimus |
| CA2942083C (en) | 2007-04-26 | 2019-01-29 | Sigmoid Pharma Limited | Manufacture of multiple minicapsules |
| CN102470106B (zh) | 2009-05-18 | 2015-09-23 | 希格默伊德药业有限公司 | 包含油滴的组合物 |
| CA2770570A1 (en) | 2009-08-12 | 2011-02-17 | Sigmoid Pharma Limited | Immunomodulatory compositions comprising a polymer matrix and an oil phase |
| GB201020032D0 (en) | 2010-11-25 | 2011-01-12 | Sigmoid Pharma Ltd | Composition |
| GB201212010D0 (en) | 2012-07-05 | 2012-08-22 | Sigmoid Pharma Ltd | Formulations |
| GB201319791D0 (en) | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
| US12109218B2 (en) | 2014-12-09 | 2024-10-08 | Aratana Therapeutics, Inc. | Compositions of grapiprant and methods for using the same |
| KR102270323B1 (ko) | 2014-03-06 | 2021-06-29 | 아라타나 세라퓨틱스, 인크. | 그라피프란트의 조성물 및 이를 사용하기 위한 방법 |
| BR112017009510A2 (pt) | 2014-11-07 | 2017-12-19 | Sigmoid Pharma Ltd | composições compreendendo ciclosporina |
| WO2016112312A1 (en) * | 2015-01-09 | 2016-07-14 | Jaguar Animal Health | Methods of treating diarrhea in companion animals |
| EP4125874A4 (en) * | 2020-03-25 | 2024-05-01 | SRI International | LIPOXYGENASE INHIBITORS |
| US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
| KR102404883B1 (ko) | 2020-11-30 | 2022-06-07 | (주)이노보테라퓨틱스 | 벤즈브로마론을 포함하는 켈로이드 또는 비대흉터 예방 또는 치료용 약학 조성물 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3896145A (en) * | 1972-07-24 | 1975-07-22 | Hoffmann La Roche | Carbazoles |
| CA1319886C (en) * | 1987-02-03 | 1993-07-06 | Alberto Ferro | Mixed micelle solutions |
-
1998
- 1998-03-02 DZ DZ980089A patent/DZ2479A1/xx active
- 1998-04-30 TW TW087106689A patent/TW590773B/zh not_active IP Right Cessation
- 1998-05-01 YU YU55899A patent/YU55899A/sh unknown
- 1998-05-01 HU HU0001286A patent/HUP0001286A3/hu unknown
- 1998-05-01 JP JP10547869A patent/JP2000513020A/ja active Pending
- 1998-05-01 WO PCT/IB1998/000662 patent/WO1998050033A1/en not_active Ceased
- 1998-05-01 EP EP98915041A patent/EP0988034A1/en not_active Withdrawn
- 1998-05-01 EA EA199900895A patent/EA003696B1/ru not_active IP Right Cessation
- 1998-05-01 SK SK1481-99A patent/SK148199A3/sk unknown
- 1998-05-01 AU AU69321/98A patent/AU6932198A/en not_active Abandoned
- 1998-05-01 IL IL13257098A patent/IL132570A0/xx unknown
- 1998-05-01 KR KR10-2003-7005258A patent/KR20040004406A/ko not_active Ceased
- 1998-05-01 CN CN98804845A patent/CN1255059A/zh active Pending
- 1998-05-01 ID IDP980651A patent/ID21311A/id unknown
- 1998-05-01 BR BR9808720-7A patent/BR9808720A/pt not_active IP Right Cessation
- 1998-05-01 KR KR1019997010252A patent/KR20010012300A/ko not_active Ceased
- 1998-05-01 PL PL98337003A patent/PL337003A1/xx unknown
- 1998-05-01 NZ NZ500183A patent/NZ500183A/en unknown
- 1998-05-01 CA CA002288759A patent/CA2288759A1/en not_active Abandoned
- 1998-05-04 GT GT199800063A patent/GT199800063A/es unknown
- 1998-05-04 UY UY24989A patent/UY24989A1/es not_active Application Discontinuation
- 1998-05-04 MA MA25059A patent/MA26491A1/fr unknown
- 1998-05-04 ZA ZA9803722A patent/ZA983722B/xx unknown
- 1998-05-04 PE PE1998000335A patent/PE72599A1/es not_active Application Discontinuation
- 1998-05-04 AP APAP/P/1998/001234A patent/AP9801234A0/en unknown
- 1998-05-04 TN TNTNSN98059A patent/TNSN98059A1/fr unknown
- 1998-05-05 HR HR60/045,635A patent/HRP980244A2/hr not_active Application Discontinuation
- 1998-05-05 AR ARP980102089A patent/AR011726A1/es unknown
- 1998-05-05 PA PA19988450601A patent/PA8450601A1/es unknown
-
1999
- 1999-10-19 IS IS5220A patent/IS5220A/is unknown
- 1999-11-02 OA OA9900242A patent/OA11213A/en unknown
- 1999-11-03 BG BG103852A patent/BG103852A/xx unknown
- 1999-11-04 NO NO995389A patent/NO995389L/no not_active Application Discontinuation
-
2003
- 2003-04-09 AR ARP030101251A patent/AR039628A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9808720A (pt) | Carprofeno seletivo para cox-2 para tratamento de dor e inflamação em cães | |
| Fish et al. | The expression of endothelial nitric-oxide synthase is controlled by a cell-specific histone code | |
| CY1107729T1 (el) | Φαρμακευτικες συνθεσεις | |
| ATE527022T1 (de) | Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie | |
| EA200200246A1 (ru) | Композиция, содержащая нестероидное противовоспалительное средство (nsaid) и ингибитор киназы egfr, для лечения или ингибирования полипов в ободочной кишке и рака ободочной и прямой кишки | |
| BR9814147A (pt) | "derivados de ácido carboxìlico e hidroxâmico tendo atividade inibitória de mmp e tnf" | |
| NO963568D0 (no) | Farmasöytisk preparat for behandling av blodkoagulasjonssykdommer, fremgangsmåter for fremstilling av dette og dets anvendelse | |
| PT944631E (pt) | Novos derivados substituidos de pirazole para tratamento de doencas cardiovasculares | |
| ATE369848T1 (de) | Verwendung von d-serine oder d-alanine zur behandlung von schizophrenie | |
| ATE234090T1 (de) | Kombination von duloxetin mit nichtsteroid- entzündungshemmern für die behandlung von schmerz | |
| BR0011172A (pt) | Derivados do 4,5-diaril-3(2h)-furanona como inibidores de cliclooxigenase-2 | |
| BR0206381A (pt) | Derivados do ácido fumárico como inibidor de nf-kappab | |
| ATE407676T1 (de) | Topoisomerasehemmern zur behandlung von chirurgischen verklebungen | |
| PT1039895E (pt) | Utilizacao de acidos 3-benzoilfenilaceticos respectivos esteres ou amidas para o tratamento do glaucoma glc1a | |
| ATE357438T1 (de) | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems | |
| Ventura-Martínez et al. | Peripheral involvement of the nitric oxide–cGMP pathway in the indomethacin-induced antinociception in rat | |
| BR9910539A (pt) | Derivados de 2 - (2 - clorofenil) - 3,4 - dihidro - 2h - pirrol | |
| Kumar et al. | Sex-specific epigenetic programming in renal fibrosis and inflammation | |
| Wheeler et al. | Cyclooxygenase-2 protein and prostaglandin E2 production are up-regulated in a rat bladder inflammation model | |
| BR9910678A (pt) | Composto, composição farmacêutica, método para traramento ou prevenção de uma doença inflamatória, método para tratamento de uma condição ou uma doença mediada por mmps, tnf, agrecanase, ou um composto dos mesmos, em um mamìfero, método de redução de nìveis de tnf em pacientes, sem a inibição de mmps, método para tratamento de uma condição ou uma doença e uso de um novo composto | |
| Oka et al. | Involvement of peroxynitrite and hydroxyradical generated from nitric oxide in hypoxia/reoxygenation injury in rat cerebrocortical slices | |
| DK1154766T3 (da) | Anvendelse af R-arylpropionsyre til fremstilling af lægemidler til behandling af sygdomme hos mennesker og dyr, hvor sygdommene kan påvirkes terapeutisk ved inhibering af aktiveringen af NF-kappa B | |
| CY1106155T1 (el) | Χρηση παραγωγων 3-βενζολοφαινυλοξικων οξεων για την αντιμετωπιση διαταραχων του αμφιβληστροειδους | |
| Belichard et al. | Pharmacological and molecular evidence for kinin B1 receptor expression in urinary bladder of cyclophosphamide‐treated rats | |
| Peskar et al. | Interaction of cyclooxygenase-2 inhibitors and salicylate in gastric mucosal damage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A E 9A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1908 DE 31/07/2007. |